$SN

Quigley Adam sold $322K of SN

Quigley Adam (Chief Financial Officer) sold 1,750 shares of SharkNinja, Inc. (SN) at $183.94 ($0.32M total) on 2026-08-07.

Original reporting
SEC EDGAR · Quigley Adam
Published Aug 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SN
Neutral
medium confidence
Mentioned
$SN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the disclosure lacks any new guidance, contract, litigation, or operational update.

02

Market read

A disclosed insider sale totaling about $322k is unlikely to be a standalone driver of price action absent corroborating fundamental news.

03

What to watch

The filing does not state a 10b5-1 plan, but it also does not provide context for why the sale occurred; without additional filings or follow-on buying, signal quality is low.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10 after-hours; sale dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for SharkNinja, Inc. (SN) by CFO Adam Quigley.

Company-level read

Ticker impact

$SNNeutralMedium confidence
Context

SharkNinja CFO Adam Quigley filed a Form 4 selling 1,750 shares at $183.9440 on 2026-08-07, totaling $321,902.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven rather than trend-changing.

Evidence & confidence

Form 4 insider sales are common and the filing provides no new company-specific operational or financial information. The absence of a stated 10b5-1 plan can raise interpretive noise, but the disclosed size ($321.9k) is typically not material enough to drive repricing by itself.

Market effects

No clear sector read-through from a single CFO open-market sale.

None indicated.

None indicated.

Counterpoint

The sale could be unrelated to fundamentals (taxes, diversification, planned liquidity needs), so it may not signal reduced confidence.

Key entities

  • SharkNinja, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Adam Quigley

    CFO who sold 1,750 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SNHighAI 8/10

Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports

Smith & Nephew's merger talks with Johnson & Johnson's orthopaedics unit collapsed over disagreement on the CEO role, according to the Financial Times. The deal would have valued the unit at up to $22 billion, nearly double Smith & Nephew's market cap. Both companies were aligned on financial terms but disagreed on leadership. Smith & Nephew's former CEO left in 2019 over pay demands.

$SNMed

UBS sees attractive risk/reward in three European medtech into Q3 results

UBS identifies Convatec, Smith & Nephew, and Sonova as attractive European medtech stocks ahead of Q3 results, citing revenue and earnings growth expectations. Convatec is expected to report 6% organic growth, Smith & Nephew may undergo a strategic review, and Sonova could raise guidance due to market growth and currency tailwinds. UBS provides price targets for each company.

$SNHighAI 8/10

Blowout Guidance Sends SharkNinja Shares Higher

SharkNinja (SN) reported Q2 2026 net sales of $1.77B (up 22.2% YoY) and adjusted net income of $178M (up 29%). The company raised full-year 2026 guidance, targeting up to 17% sales growth and $6.55 adjusted EPS. SN shares have risen 56% YTD, supported by institutional demand and strong fundamentals, including 3-year sales growth of 20% and EPS growth of 63.8%.

$SNMed

UBS raises SharkNinja stock price target to $219 on product expansion

UBS raised its price target for SharkNinja (NYSE:SN) to $219.10 from $147 and kept a Buy rating, citing Q2 results and faster product launches. The firm pointed to 13 new products year to date versus nine in the first eight months of 2025, plus plans for up to three new subcategories in 2026. SN trades at $187.68 and reported revenue of $1.77B (+22.2%) with adjusted EPS of $0.92.